APR-246 and Novobiocin Strike TP53-Mutant AML Through Two Vulnerabilities
TP53-mutant AML remains one of the hardest hematologic malignancies to treat. These leukemias tend to arise in older, frail patients, and the malignant clones are often resistant to standard therapy. Median survival in this setting is typically measured in months, not years, which is why any regimen that can push these cells into a deeper biologic trap draws immediate attention.
This preclinical study tests a combination built around that problem: APR-246, a compound developed to target mutant p53 but also known to disturb redox balance, and novobiocin, an inhibitor of DNA polymerase theta, or Polθ. In isogenic MOLM13 AML cell lines carrying common TP53 variants, the pair worked far better together than either agent alone. The strongest effect appeared in TP53-mutant cells, but some activity also emerged in wild-type and null cells, suggesting more than one killing pathway was involved.
DNA Damage Repair Becomes a Liability
APR-246 is converted into an active compound, MQ, and that conversion releases formaldehyde. Formaldehyde can generate DNA-protein crosslinks, the kind of lesion that forces cancer cells to rely on backup repair machinery. Polθ sits in that repair network. When it is inhibited, cells lose a key route for resolving the damage created by APR-246’s chemistry.
Novobiocin, used here as a Polθ inhibitor, therefore appears to turn a DNA repair dependency into a vulnerability. Instead of letting the leukemia cell recover from crosslinked DNA, the combination leaves it with accumulating damage and limited escape routes. In TP53-mutant cells, where genomic stress is already high, that added burden is especially punishing.
The effect was not confined to one genetic background. Strong synergy emerged across all TP53-mutant cell lines tested, while the wild-type and null models showed a weaker but still measurable response. That pattern points to overlapping mechanisms: one that depends on mutant p53 biology and another that acts independently of p53 status.
Ferroptosis and Apoptosis Pull in the Same Direction
The killing signal did not rely on a single form of cell death. APR-246 provided selectivity for TP53-mutated cells, while novobiocin amplified p53-independent apoptosis and p53-dependent ferroptosis. Ferroptosis is particularly relevant in this setting because Polθ also helps protect cells from it. Blocking Polθ while driving redox stress may remove a brake on lipid peroxidation and oxidative injury, allowing the leukemic cell to collapse from within.
A single sentence captures the practical implication: the combination attacks both the repair system and the antioxidant defenses that TP53-mutant AML cells lean on for survival.
The study also reports that levels of ferroptosis induction tracked with the observed synergy in TP53-mutant and wild-type cells. In other words, the more the treatment pushed cells toward ferroptotic death, the stronger the combined effect became. That alignment strengthens the biologic logic of the pairing and suggests that ferroptosis is not just a bystander readout but part of the mechanism of action.
Primary Patient Samples Responded at Low Exposure
The most clinically relevant part of the preclinical package came from primary TP53-mutated AML and CMML samples. Combination treatment produced potent in vitro growth inhibition in those patient cells, with significant activity achieved at low micromolar or nanomolar concentrations of APR-246. For a disease defined by resistance and clonal persistence, activity in primary material matters more than cell-line performance alone.
This is also where the redox biology becomes more than a laboratory detail. TP53-mutant blasts often survive by managing oxidative injury and DNA damage better than expected. APR-246 disrupts that balance, and novobiocin appears to prevent the cell from repairing the resulting lesions or buffering the downstream stress. The dual hit may therefore be especially relevant in leukemias that have already evolved around p53 loss or mutation.
Why This Combination Fits the Biology of TP53-Mutant AML
The authors frame the strategy as one tailored to a disease subset with few effective options and poor prognosis. That framing is reasonable. TP53-mutant AML is not just a genetically defined category; it is a biologically aggressive state marked by repair defects, stress tolerance, and treatment escape. A regimen that couples DNA-protein crosslink generation with Polθ inhibition is appealing because it exploits exactly those pressures.
There is also a broader translational point. APR-246 has already shown favorable safety in a phase 3 trial in TP53-mutant MDS and AML, even though the earlier combination with azacitidine failed to meet efficacy endpoints. The current work suggests that the problem may not be APR-246 itself, but the partner drug. A more effective companion could convert an active scaffold into a clinically useful regimen.
What Still Has to Be Proven in Patients
The evidence here is preclinical, and that matters. Cell-line synergy and ex vivo activity in patient samples are necessary steps, not proof of clinical benefit. Dosing, tolerability, pharmacokinetics, and on-target toxicity all remain unresolved in humans. Novobiocin’s role as a Polθ inhibitor also needs confirmation in a clinical development program built for leukemia rather than repurposed from its historical use as an antibiotic-class compound.
Competing interests were disclosed, including relationships involving investigators connected to companies developing mutant p53 or DNA damage response therapies. Those ties do not negate the biology, but they do sharpen the need for independent replication before this combination moves forward as a therapeutic strategy.
Even so, the mechanistic fit is unusually tight: APR-246 generates the damage, Polθ inhibition blocks repair, and ferroptosis plus apoptosis push the leukemia cell past recovery. The unanswered question is no longer whether the biology is plausible. The next step is whether that same pressure can be delivered safely and effectively in patients with TP53-mutant AML and related myeloid neoplasms.